TY - JOUR
T1 - Gastrointestinal involvement in systemic sclerosis
T2 - An update
AU - McMahan, Zsuzsanna H.
N1 - Funding Information:
This work was supported by NIH/NIAMS K23 award and The Scleroderma Research Foundation ( NIH/NIAMS K23 AR071473 to Z.H.M; Scleroderma Research Foundation to Z.H.M. ).
Publisher Copyright:
© 2019 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2019/11/1
Y1 - 2019/11/1
N2 - Purpose of reviewThis review provides important updates in systemic sclerosis (SSc)-related gastrointestinal disease, specifically focusing on the most recent literature.Recent findingsIn the past year, several studies were published that present interesting insights into SSc and gastrointestinal disease. Studies focusing on newly identified risk factors, novel approaches to diagnosis and assessment of disease activity, survival and quality of life demonstrate progress in our understanding of this challenging area. Additional data on specific SSc gastrointestinal-related topics, such as the link between gastrointestinal and pulmonary disease, nutrition, and the microbiome, are also now available.SummarySSc gastrointestinal disease is heterogeneous in its clinical presentation, which presents a challenge in diagnosis and management. In the past year, several studies have evaluated risk factors and clinical features associated with specific gastrointestinal complications in SSc. Objective gastrointestinal testing may help to identify specific SSc gastrointestinal subgroups and provide diagnostic accuracy to guide targeted therapies. Survival in very early SSc is affected by the severity of gastrointestinal involvement. Other important gastrointestinal subsets, including patients with esophageal disease and interstitial lung disease, should carefully be considered when developing a management plan for this patient population.
AB - Purpose of reviewThis review provides important updates in systemic sclerosis (SSc)-related gastrointestinal disease, specifically focusing on the most recent literature.Recent findingsIn the past year, several studies were published that present interesting insights into SSc and gastrointestinal disease. Studies focusing on newly identified risk factors, novel approaches to diagnosis and assessment of disease activity, survival and quality of life demonstrate progress in our understanding of this challenging area. Additional data on specific SSc gastrointestinal-related topics, such as the link between gastrointestinal and pulmonary disease, nutrition, and the microbiome, are also now available.SummarySSc gastrointestinal disease is heterogeneous in its clinical presentation, which presents a challenge in diagnosis and management. In the past year, several studies have evaluated risk factors and clinical features associated with specific gastrointestinal complications in SSc. Objective gastrointestinal testing may help to identify specific SSc gastrointestinal subgroups and provide diagnostic accuracy to guide targeted therapies. Survival in very early SSc is affected by the severity of gastrointestinal involvement. Other important gastrointestinal subsets, including patients with esophageal disease and interstitial lung disease, should carefully be considered when developing a management plan for this patient population.
KW - diagnosis
KW - dysmotility
KW - gastrointestinal
KW - management
KW - systemic sclerosis
UR - http://www.scopus.com/inward/record.url?scp=85072791643&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072791643&partnerID=8YFLogxK
U2 - 10.1097/BOR.0000000000000645
DO - 10.1097/BOR.0000000000000645
M3 - Review article
C2 - 31389815
AN - SCOPUS:85072791643
SN - 1040-8711
VL - 31
SP - 561
EP - 568
JO - Current opinion in rheumatology
JF - Current opinion in rheumatology
IS - 6
ER -